Translational research as prerequisite for personalized psychiatry

Keck, Martin E.; Kappelmann, Nils; Kopf‐Beck, Johannes

doi:10.1007/s00406-018-0885-3

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, another direction for future research is the concurrent assessment of approach-avoidance biases and related behaviours for multiple substances. Such research will further our understanding of the shared mechanisms underlying these disorders in line with a transdiagnostic approach, which advocates for the assessment of interdependent processes and behaviours [84]. Indeed, transdiagnostic research on approach bias will have implications for modification paradigms aiming to target multiple excessive consumption behaviours.…”

Section: Implications For Future Researchmentioning

confidence: 98%

Assessment of Automatically Activated Approach–Avoidance Biases Across Appetitive Substances

et al. 2019

View full text Add to dashboard Cite

Purpose of Review Automatic approach-avoidance tendencies drive excessive intake of drugs and unhealthy food. Dual-process models of behaviour propose that strong approach biases predict excessive intake when reflective processes are weak. Consistent with theory, early findings indicated that approach biases predicted excessive use of drugs, including alcohol and tobacco. Given that reviews on approach bias for appetitive substances are lacking, the current review aimed to synthesise the recent findings on automatic approach biases across three of the most commonly assessed substances: alcohol, food and tobacco. Recent Findings The findings suggest that approach biases exist for a range of substances, are mostly stronger in clinical samples than healthy controls and predict consumption behaviour, albeit under certain conditions. Summary Approach biases for appetitive substances are related to excessive consumption in line with theoretical premises. Further longitudinal research is needed, particularly in the domains of tobacco and food, to determine the prediction of consumption of these substances over time. Nevertheless, the findings highlight a continued need for approach bias modification techniques aimed at changing this underlying mechanism.

show abstract

Section: Implications For Future Researchmentioning

confidence: 98%

Assessment of Automatically Activated Approach–Avoidance Biases Across Appetitive Substances

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In the current research, we follow this strategy and apply a similar multi-variate approach as it was suggested in the past [83,85,86] by including variables from self-reports (e.g. symptoms or personality traits), sociodemographics (e.g.…”

Section: Exploring Predictors Of Treatment Responsementioning

confidence: 99%

Schema therapy versus cognitive behavioral therapy versus individual supportive therapy for depression in an inpatient and day clinic setting: study protocol of the OPTIMA-RCT

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Major depressive disorder represents (MDD) a major cause of disability and disease burden. Beside antidepressant medication, psychotherapy is a key approach of treatment. Schema therapy has been shown to be effective in the treatment of psychiatric disorders, especially personality disorders, in a variety of settings and patient groups. Nevertheless, there is no evidence on its effectiveness for MDD in an inpatient nor day clinic setting and little is known about the factors that drive treatment response in such a target group. Methods In the current protocol, we outline OPTIMA (OPtimized Treatment Identification at the MAx Planck Institute): a single-center randomized controlled trial of schema therapy as a treatment approach for MDD in an inpatient and day clinic setting. Over the course of 7 weeks, we compare schema therapy with cognitive behavioral therapy and individual supportive therapy, conducted in individual and group sessions and with no restrictions regarding concurrent antidepressant medication, thus approximating real-life treatment conditions. N = 300 depressed patients are included. All study therapists undergo a specific training and supervision and therapy adherence is assessed. Primary outcome is depressive symptom severity as self-assessment (Beck Depression Inventory-II) and secondary outcomes are clinical ratings of MDD (Montgomery-Asberg Depression Rating Scale), recovery rates after 7 weeks according to the Munich-Composite International Diagnostic Interview, general psychopathology (Brief Symptom Inventory), global functioning (World Health Organization Disability Assessment Schedule), and clinical parameters such as dropout rates. Further parameters on a behavioral, cognitive, psychophysiological, and biological level are measured before, during and after treatment and in 2 follow-up assessments after 6 and 24 months after end of treatment. Discussion To our knowledge, the OPTIMA-Trial is the first to investigate the effectiveness of schema therapy as a treatment approach of MDD, to investigate mechanisms of change, and explore predictors of treatment response in an inpatient and day clinic setting by using such a wide range of parameters. Insights from OPTIMA will allow more integrative approaches of psychotherapy of MDD. Especially, the identification of intervention-specific markers of treatment response can improve evidence-based clinical decision for individualizing treatment. Trial registration Identifier on clinicaltrials.gov: NCT03287362; September, 12, 2017

show abstract

Translational research as prerequisite for personalized psychiatry

Cited by 2 publications

References 9 publications

Assessment of Automatically Activated Approach–Avoidance Biases Across Appetitive Substances

Assessment of Automatically Activated Approach–Avoidance Biases Across Appetitive Substances

Schema therapy versus cognitive behavioral therapy versus individual supportive therapy for depression in an inpatient and day clinic setting: study protocol of the OPTIMA-RCT

Contact Info

Product

Resources

About